Genetic Factors and Citalopram Response
Author Information
Author(s): Eric J. Peters, Susan L. Slager, Jeffrey B. Kraft, Greg D. Jenkins, Megan S. Reinalda, Patrick J. McGrath, Steven P. Hamilton
Primary Institution: University of California San Francisco
Hypothesis
Is clinical response or tolerance to citalopram associated with genetic polymorphisms in pharmacokinetic enzymes?
Conclusion
No genetic polymorphism in the pharmacokinetic genes examined was significantly associated with response or tolerance to citalopram.
Supporting Evidence
- The study involved a large sample size of 1,953 subjects.
- No significant associations were found in both discovery and validation stages.
- The study utilized a two-stage design to control Type I error.
Takeaway
The study looked at whether genes affect how well people respond to the antidepressant citalopram, but found that they don't.
Methodology
A two-stage case-control study design was used, splitting 1,953 subjects from the STAR*D trial into discovery and validation sets, examining 15 polymorphisms from five pharmacokinetic genes.
Potential Biases
Potential bias due to self-reported ethnicity and the non-random selection of subjects for genetic analysis.
Limitations
Population stratification may obscure true associations, and the study was not explicitly designed for pharmacogenetic analysis.
Participant Demographics
The sample was 61.8% female, 78.1% Caucasian, 16.1% African-American, and 5.8% other races.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website